GHK-Cu: What Do 50 Years of Copper Peptide Studies REALLY Say?
The straight answer: as a cream or gel, GHK-Cu has 50 years of lab and animal work and a handful of small human studies, with mixed results. As an injection, it has no published human trials. It is not an approved drug in the US or Canada, and Health Canada has named injectable GHK-Cu in a warning about unauthorized peptides.
In 1973, a researcher named Loren Pickart reported a tiny peptide in human blood that kept liver cells alive longer in the lab (Pickart & Thaler, Nature New Biology, 1973, PMID 4349963). Fifty-three years later, that peptide is an electric-blue serum on drugstore shelves, and a liquid people draw into syringes at home (NPR, September 7, 2026).
The only randomized trial of GHK-Cu skin care on faces that we found in PubMed had 13 patients. Blinded evaluators measured one result. The patients reported another.
Also known as: GHK-Cu, GHK Cu, GHKCu, ghkcu, copper peptide, copper peptides, copper tripeptide-1, glycyl-L-histidyl-L-lysine copper, prezatide copper acetate, Iamin
Research use only. This is research information, not medical advice. Nothing here recommends using, dosing, stopping, or combining any product. A licensed clinician decides whether treatment is appropriate.
Research snapshot
- 12Studies reviewed
- 4Human studies
- 1Registry records
Evidence Facts
Graded for Diabetic foot-ulcer closure (topical gel)
- 4 4 of 4 · Strong human proof 0
- 3 3 of 4 · Good human proof 0
- 2 2 of 4 · Needs more proof 2
- 1 1 of 4 · Not proven in people 4
Limited human evidence. Grades are updated as new studies publish. How we grade evidence
Status by country
Not approved in the US and CanadaUnited States
- Authorization
- Not an FDA-approved drug
- Cosmetics
- Creams and serums are sold as a cosmetic ingredient (copper tripeptide-1)
- Compounding
- Since May 14, 2026, GHK-Cu except for injectable routes is in 503A Category 1 (under evaluation). Injectable GHK-Cu is nominated-but-withdrawn
Canada
- Injectables
- Named in the Health Canada April 9, 2026 advisory on unauthorized injectable peptides
- Recall
- Type I recall of GHK-Cu powder lots, May 7, 2026 (RA-82047)
- Cosmetics
- Creams are sold as cosmetics and must be notified to Health Canada
Other countries
- Coverage
- Not reviewed for this profile
Full detail and sources are in Status and access by country.
On this page
The short answer
Evidence so far: human studies and laboratory and animal studies.
GHK-Cu is a three-amino-acid peptide (glycine, histidine, lysine) bound to a copper ion. Your blood carries small amounts of GHK. Pickart's 2015 review puts the level at about 200 ng/mL at age 20 and 80 ng/mL by age 60 (Pickart et al., 2015, PMID 26236730).
In lab dishes and animals, GHK-Cu raises collagen production and speeds wound repair. In people, the record is thin and split. One multicenter trial of a GHK-Cu gel on diabetic foot ulcers reported faster closure (Mulder et al., 1994, PMID 17147644). A trial of a tripeptide-copper cream on leg ulcers in 86 patients found it no better than placebo (Bishop et al., 1992, PMID 1495150). After laser resurfacing, a 13-patient trial found no measurable difference (Miller et al., 2006, PMID 16847171).
A 2025 review of topical GHK as an anti-wrinkle ingredient described "a surprising absence of clinical studies" using GHK-Cu (Mortazavi et al., 2025, PMID 39963574). A 2026 evidence-mapping review concluded GHK-Cu "should be regarded as a promising but unproven therapeutic cargo rather than a clinically validated regenerative drug" (Mateescu et al., 2026, PMID 42797253).
Where it sits next to other compounds is on peptides ranked by evidence. Why that gap between lab results and human proof keeps showing up is the subject of what are peptides.
What it is
GHK stands for glycyl-L-histidyl-L-lysine. It is a tripeptide, a chain of three amino acids. GHK grabs copper (II) ions tightly, and the copper-bound form is GHK-Cu.
On cosmetic ingredient lists, GHK-Cu appears as copper tripeptide-1. Its drug name is prezatide copper acetate. In the 1990s, a wound gel built on it was tested under the name Iamin (Mulder et al., 1994).
Do not mix it up with AHK-Cu (alanyl-histidyl-lysine copper). That is a different copper peptide, and it matters for the hair section below.
"Copper peptides" on a label can mean GHK-Cu or a blend. Formulation changes what reaches the skin: the 2026 Mateescu review found that most studies do not report how much of the copper is bound to the peptide, or how much free copper is released (PMID 42797253).
Why it is being studied
Three findings put GHK-Cu on the map.
First, it occurs in the body and declines with age (Pickart's figures above). That led to the idea that topping it up might restore some repair capacity. The decline is a measured correlation. Whether adding GHK-Cu back reverses aging has not been tested in people.
Second, in cell cultures, GHK-Cu switched on collagen production in fibroblasts, the cells that build skin's support layer, starting at extremely low concentrations (Maquart et al., 1988, PMID 3169264).
Third, gene-expression screens. In 2012, Boston University researchers used the Broad Institute's Connectivity Map, a database of how drugs shift gene activity in lab-grown cells, to search for compounds that reverse the gene pattern of emphysema. GHK came out on top. In their lab work, GHK restored collagen remodeling by lung fibroblasts taken from COPD patients (Campbell et al., Genome Medicine, 2012, PMID 22937864).
That gene data is the source of a claim you will see on almost every product page.
What the human studies show
Every human study we found applied GHK-Cu to the skin or a wound. Here they are, best-controlled first.
Diabetic foot ulcers (positive). A multicenter, randomized, evaluator-blinded, placebo-controlled trial tested Iamin gel alongside standard wound care. Median closure of plantar ulcers was 98.5% with the gel versus 60.8% with the inactive gel. Among plantar ulcers treated right after debridement, infections were lower too: 7% versus 34% (Mulder et al., 1994, PMID 17147644). The abstract does not give the number of patients. The gel never became an approved drug, and we found no follow-up trial.
Venous leg ulcers (negative). In 86 evaluable patients, a 0.4% tripeptide-copper cream did no better than placebo. Silver sulfadiazine, an old antibacterial cream, beat both (Bishop et al., 1992, PMID 1495150). The abstract does not spell out the peptide's name.
After CO2 laser resurfacing (negative on objective measures). Thirteen patients were randomized to skin care with or without GHK-Cu. Computer analysis and blinded evaluators found no difference in redness, wrinkles or overall skin quality. The patients using GHK-Cu rated their skin as more improved (P = .04) (Miller et al., 2006, PMID 16847171).
That split,
nothing on the measuring tools and a better score on the questionnaire
, is what a placebo effect can look like. It is also what a small benefit too subtle for 13 people can look like. A 13-patient trial cannot tell them apart.Facial creams (unpublished). Pickart's 2015 review describes three 12-week cream studies in 71, 41 and 67 women, reporting less wrinkling and denser skin (PMID 26236730). The review cites them to Leyden, 2002, with no journal listed. We could not find them in PubMed, so we cannot check their methods.
Scalp (not a GHK-Cu test). A 2024 open-label study of adults with dandruff used a scrub plus a serum containing copper tripeptide-1 and four other actives, with no control group. The product maker employed one author (Patel et al., Cureus, 2024, PMID 39449909). It cannot isolate what GHK-Cu did.
Injection: none. We found no published human study of injected GHK-Cu. FDA says there are "limited data in humans to inform safety-related considerations" for injectable GHK-Cu (FDA). A 60-person phase 2 trial of a topical GHK-Cu gel on small skin wounds began recruiting in February 2026. It has no results yet (NCT07437586).
What laboratory and animal studies show
Most of the research so far comes from laboratory and animal studies. That does not tell us whether it works in people.
Pickart's 2015 review summarizes the lab and animal record: wound healing in rats, mice, pigs and dogs, more collagen and decorin (a molecule that helps organize collagen) in cell cultures, and recovery of fibroblasts damaged by radiation (PMID 26236730). Much of that literature comes from the group that discovered GHK.
Hair. The study most often cited for "copper peptides grow hair" tested AHK-Cu, not GHK-Cu. Korean researchers found AHK-Cu lengthened human hair follicles kept alive in a dish and helped dermal papilla cells (the cells that drive hair growth) multiply (Pyo et al., 2007, PMID 17703734). That is a follicle in a dish, treated with a different peptide. It is not hair regrowth on a scalp.
Skin penetration. GHK dissolves easily in water and passes through skin's outer barrier poorly. The 2025 Mortazavi review lists microneedles and chemical modifications as ways researchers are trying to push more of it in (PMID 39963574). How much of a given serum reaches living skin cells is an open question.
Evidence by outcome
| Effect | Evidence | ||
|---|---|---|---|
| Human randomized trials 3 outcomes · 3 studies | |||
| Diabetic foot-ulcer closure (topical gel) | Certainty 2 of 4 · Needs more proof | Effect Diabetic foot-ulcer closure (topical gel): favorable, 98.5% vs 60.8% median closure | Evidence 1 study Show details Hide detailsApplicabilityOne randomized, evaluator-blinded, placebo-controlled trial (Mulder et al., 1994). The gel never became an approved drug, and no follow-up trial was found. Supporting studies |
| Venous leg-ulcer closure (topical cream) | Certainty 2 of 4 · Needs more proof | Effect Venous leg-ulcer closure (topical cream): no clear difference | Evidence 1 study Show details Hide detailsApplicabilityThe abstract does not spell out the peptide's name. Silver sulfadiazine, an old antibacterial cream, beat both the tripeptide-copper cream and placebo. Supporting studies |
| Redness, wrinkles after laser resurfacing | Certainty 1 of 4 · Not proven in people | Effect Redness, wrinkles after laser resurfacing: no clear difference | Evidence 1 study Show details Hide detailsApplicabilityComputer analysis and blinded evaluators found no difference in redness, wrinkles or overall skin quality. Patients using GHK-Cu rated their skin as more improved (P = .04). A 13-patient trial cannot tell a placebo effect apart from a small benefit. Supporting studies |
| Human observational studies 1 outcome · 1 study | |||
| Wrinkles and skin density (facial creams) | Certainty 1 of 4 · Not proven in people | Effect Wrinkles and skin density (facial creams): not assessed | Evidence 1 study Show details Hide detailsApplicabilityPickart's 2015 review (PMID 26236730) cites them to Leyden, 2002, with no journal listed. They were not found in PubMed, so the methods are not checkable. Supporting studies |
| Animal and laboratory studies 2 outcomes · 1 study | |||
| Hair growth | Certainty 1 of 4 · Not proven in people | Effect Hair growth: not assessed | Evidence 1 study Show details Hide detailsApplicabilityAHK-Cu, not GHK-Cu. A follicle in a dish, treated with a different peptide. It is not hair regrowth on a scalp. Supporting studies |
| Anything, by injection No animal or laboratory studies identified for this outcome in our reviewed sources. | Certainty 1 of 4 · Not proven in people | Effect Anything, by injection: not assessed | Evidence 0 studies Show details Hide detailsApplicabilityNo supporting human studies. FDA says there are "limited data in humans to inform safety-related considerations" for injectable GHK-Cu (FDA safety page: https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks). |
Grades are updated as new studies publish. How we grade evidence
How researchers think it works
GHK-Cu's proposed actions come from cell and animal studies. In cultures, it raises collagen synthesis by fibroblasts (Maquart et al., 1988). It also carries copper, a mineral that collagen-crosslinking enzymes need.
The "4,000 genes" claim. Pickart's 2015 review says GHK can "up- and downregulat[e] at least 4,000 human genes, essentially resetting DNA to a healthier state" (PMID 26236730). The number traces back to one database. Pickart's team took the Connectivity Map's three GHK gene profiles, all from two lab-grown cancer cell lines (PC3 prostate and MCF7 breast), and counted genes that moved by 50% or more. They reported 31.2% (Pickart et al., 2014, PMID 25302294).
So the figure describes cancer cells in a dish. It does not show that GHK-Cu changes gene activity in a living person, and it does not say whether those changes are good. "Resetting DNA" is the authors' interpretation. The DNA sequence itself does not change in a gene-expression study.
Safety and unanswered questions
On the skin. The human trials above did not report serious harms, but they were small and short. Skincare users on Reddit describe irritation and a worsening they call the "copper uglies." That term is not in any study we found, and we could not find any controlled data on it.
By injection. FDA's safety summary says compounded injectable GHK-Cu "may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities" (FDA). Immunogenicity means the immune system may react to the product. Aggregation means peptide molecules clumping together, which can make that more likely.
Reddit users report burning and welts that last hours to a day after injecting. One Seattle-area clinician told NPR he has seen patients who injected grey-market GHK-Cu with elevated liver enzymes and elevated copper, and that it is unclear whether the peptide or an impurity caused it (NPR, 2026). That is one clinician's account, not a study.
What has not been measured. We did not find reliable interaction data in the sources reviewed. That does not mean there are no interactions. There is no published data on long-term use, pregnancy, or people with conditions that affect copper handling, such as Wilson disease (MedlinePlus).
Study context
Three things shape how to read this record.
The cosmetic studies are mostly small, short and industry-linked. NPR described them as "generally small trials funded by the cosmetic industry" (NPR, 2026).
GHK is a natural molecule, which makes it hard to patent. A University of Washington researcher who studies GHK told NPR that human trials would need huge investment and "it's probably never going to get FDA approval." That helps explain the missing trials. It is not evidence for or against the peptide.
Much of the review literature comes from Pickart and his co-authors. Independent reviews in 2025 and 2026 read the same record and called the clinical evidence thin (PMID 39963574; PMID 42797253).
Status and access by country
United States. GHK-Cu is not an FDA-approved drug. The same molecule is sold legally in creams and serums as a cosmetic ingredient. Copper peptide serums ranked by label disclosure. FDA decides cosmetic versus drug by intended use, and lists claims to "restore hair growth" or "regenerate cells" as examples of drug claims (FDA).
For pharmacy compounding, FDA split GHK-Cu by route on May 14, 2026. GHK-Cu "except for injectable routes of administration" is back in 503A Category 1 (under evaluation). Injectable GHK-Cu sits on FDA's list of substances "nominated but withdrawn" from Category 2, with FDA's safety concerns still posted (FDA 503A categories, updated May 14, 2026; FDA safety-risk page). FDA says it will consult its Pharmacy Compounding Advisory Committee on GHK-Cu before the end of February 2027.
Canada. Health Canada's April 9, 2026 advisory lists GHK-Cu among unauthorized injectable peptide drugs it has seized. It says "peptides are generally regulated as prescription drugs" and that "For Research Use Only" labels do not make products legal (Health Canada). On May 7, 2026, it posted a Type I recall of GHK-Cu powder lots sold to pharmacies as unauthorized active ingredients (Health Canada recall RA-82047). Creams are sold as cosmetics, which must be notified to Health Canada and meet the Cosmetic Regulations (Health Canada).
Other countries. We have not reviewed other regulators for this profile.
Testing and documentation
No verification reports have been reviewed for this profile. Straight Up Peptides has not purchased or commissioned testing of any GHK-Cu sample.
A dermatologist quoted by NPR put the core problem with grey-market vials plainly: "Whether or not it's even a copper peptide is always a concern" (NPR, 2026).
Common questions
Is GHK-Cu FDA approved?
No. FDA has not approved GHK-Cu as a drug for any use. Creams and serums sell legally with it as a cosmetic ingredient (copper tripeptide-1). Injectable GHK-Cu is not authorized for pharmacy compounding, and FDA plans an advisory-committee review before the end of February 2027. Full status by route: is GHK-Cu FDA approved?
Is GHK-Cu legal in Canada?
Creams and serums are sold as cosmetics. Injectable GHK-Cu is a different matter: Health Canada named it among seized unauthorized injectable peptide drugs in April 2026 and recalled GHK-Cu powder lots in May 2026.
Does topical GHK-Cu work?
The evidence is thin and mixed. A placebo-controlled trial of a GHK-Cu wound gel on diabetic foot ulcers was positive. A leg-ulcer trial and a 13-patient laser-resurfacing trial found no measurable benefit. The best-known facial-cream studies were never published in a journal we could find.
Is GHK-Cu safe to inject?
Unknown. No published human trial has tested injected GHK-Cu. FDA flags possible immune reactions from clumping and impurities, and notes limited human data.
Do copper peptides grow hair?
Not shown in people. The lab study usually cited tested AHK-Cu, a different copper peptide, on follicles in a dish. We found no controlled human trial of GHK-Cu for hair loss.
Does GHK-Cu really change 4,000 genes?
That figure comes from a database of lab-grown cancer cells, not from people. It counts genes whose activity shifted by 50% or more. It does not show the same thing happens in your skin, or that the changes help.
Are the "copper uglies" real?
It is a Reddit term for skin looking worse after starting copper peptides. We found no study that measured it.
Is GHK-Cu the same as BPC-157?
No. GHK-Cu is a three-amino-acid peptide bound to copper. BPC-157 is a 15-amino-acid peptide. They are sold together in blends, but they were studied separately, and neither has a published human injection trial.
Sources, methodology, and changes
Methodology. Literature search on 2026-10-09: PubMed (GHK-Cu, GHK, "copper tripeptide", "copper peptide", glycyl-histidyl-lysine, prezatide, Iamin; filtered for clinical trials, hair, wounds, skin aging and reviews from 2023 to 2026), ClinicalTrials.gov (GHK-Cu, copper peptide), FDA compounding pages, Health Canada advisories and recalls. Vendor pages, forum posts and news coverage were used to find primary records and to describe what readers ask, never as evidence of effect. The one news source quoted for clinical observations (NPR) is labelled as such.
Primary sources.
- Pickart & Thaler, 1973, Nature New Biology: PMID 4349963
- Maquart et al., 1988, FEBS Letters (collagen in fibroblast cultures): PMID 3169264
- Bishop et al., 1992, J Vasc Surg (venous ulcers, n=86): PMID 1495150
- Mulder et al., 1994, Wound Repair Regen (diabetic ulcers): PMID 17147644
- Miller et al., 2006, Arch Facial Plast Surg (laser resurfacing, n=13): PMID 16847171
- Pyo et al., 2007, Arch Pharm Res (AHK-Cu, hair follicles in vitro): PMID 17703734
- Campbell et al., 2012, Genome Medicine (emphysema gene signature): PMID 22937864
- Pickart et al., 2014, BioMed Res Int (gene data): PMID 25302294
- Pickart et al., 2015, BioMed Res Int (skin review): PMID 26236730
- Patel et al., 2024, Cureus (scalp regimen, open-label): PMID 39449909
- Mortazavi et al., 2025, BioImpacts (topical GHK review): PMID 39963574
- Mateescu et al., 2026, Pharmaceutics (evidence-mapping review): PMID 42797253
- ClinicalTrials.gov NCT07437586 (CuHeal, recruiting, no results): record
- FDA, 503A bulk drug substance categories (updated May 14, 2026): PDF
- FDA, Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks: page
- FDA, Is It a Cosmetic, a Drug, or Both?: page
- Health Canada advisory, April 9, 2026: RA-81874
- Health Canada recall, May 7, 2026: RA-82047
- Health Canada, Regulatory information for cosmetics: page
- NPR, "People are injecting copper peptides ahead of the science," September 7, 2026 (news, clinician quotes): story
Contributors. Written by the Evidence Research Team (a collective editorial byline; no individual credentials are claimed). No outside expert has reviewed this page. No external funding was involved.
Dates. Literature search: 2026-10-09. Published: October 9, 2026. Last updated: October 9, 2026.
Corrections. Spotted something we should check? Send us the source: /corrections/.
Keep reading
NIOD and COSRX state a GHK-Cu amountCopper peptide serums, ranked by the label
Cosmetic serums. COSRX states 0.5%. No hair-growth trial.Copper peptides for hair
No trial compares them. One brand says not to combine them.Copper peptides vs retinol
Skin trials recorded few harms. Injection has no trial.GHK-Cu side effects
Creams sell as cosmetics. The injection does not.Is GHK-Cu FDA approved?
One rat study of the pair found no added benefitBPC-157 vs TB-500: the Wolverine stack